San Diego-based Anadys Pharmaceuticals, the developer of treatments for hepatitis C, said this morning that it has agreed to be acquired by Roche. The firm said it signed a definitive merger agreement where Roche will pay $3.70 per share for all of its outstanding common stock, or a total of $230M. The price is a 256 percent premium over the $1.04 per share that Anadys was trading on Friday. Anadys said it was advised by Lazard and Cooley LLP in the deal.